Fixed-dose irbesartan/hydrochlorothiazide combination in the treatment of arterial hypertension
https://doi.org/10.51922/2616-633X.2023.7.2.2021
Abstract
Almost a third of the population of the Republic of Belarus suffers from elevated blood pressure which results in a high risk of cardiovascular disease developing. Despite the availability of numerous antihypertensive drugs, more than 40% of patients receiving antihypertensive therapy do not achieve target blood pressure levels and continue to be at an increased risk of cardiovascular events. A fixed combination drug irbesartan/hydrochlorothiazide, which includes two active ingredients in one dosage form of a tablet, is an antihypertensive combination balanced on the basis of clinical and pharmacological properties, which is approved by the Ministry of Health of the Republic of Belarus for use in patients when indicated in case of essential arterial hypertension. This fixed-dose combination is intended for adult patients whose blood pressure is not adequately controlled by irbesartan or hydrochlorothiazide monotherapy. The clinical efficacy and safety of this combination was demonstrated in randomized clinical trials, including patients with a combination of hypertension and type 2 diabetes, metabolic syndrome, and obesity. The use of the fixed-dose combination of irbesartan/hydrochlorothiazide leads to a more rapid decrease in blood pressure compared to irbesartan monotherapy, allows the majority of patients with severe hypertension to achieve the target blood pressure, and increases drug compliance. Thus, the irbesartan/hydrochlorothiazide combination is a valuable addition to clinicians’ armamentarium for the treatment of hypertension.
References
1. Arterial hypertension in adults: Clinical guidelines Russian Society of Cardiology. Russian Scientific Medical Society of Therapists, 2022. 161 p.
2. Mills K., Stefanescu A., He J. The global epidemiology of hypertension. Nature Rev Nephrol, 2020, vol. 16(4), pp. 223-237. doi: 10.1038/s41581-019-0244-2.
3. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet, 2021, vol. 398(10304), pp. 957-980. doi: 10.1016/S0140-6736(21)01330-1.
4. Lewington S., Clarke R., Qizilbash N., Peto R., Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet, 2002, vol. 360(9349), pp. 1903-1913. doi: 10.1016/s0140-6736(02)11911-8.
5. Zhou D., Xi B., Zhao M., Wang L., Veeranki S. Uncontrolled hypertension increases risk of all-cause and cardiovascular disease mortality in US adults: the NHANES III linked mortality study. Sci Rep, 2018, vol. 8(1), pp. 9418. doi: 10.1038/s41598-018-27377-2.
6. Wang Y., Alexander G., Stafford R. Outpatient hypertension treatment, treatment intensification, and control in Western Europe and the United States. Arch Intern Med, 2007, vol. 167(2), pp. 141–147. doi: 10.1001/archinte.167.2.141.
7. Cushman W., Ford C., Cutler J., et al. ALLHAT Collaborative Research Group. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens, 2002, vol. 4, pp. 393-404. doi: 10.1111/j.1524-6175.2002.02045.x.
8. STEPS: Prevalence of risk factors for noncommunicable diseases in the Republic of Belarus, 2020. Copenhagen: WHO Regional Office for Europe, 2022 License: CC BY-NC-SA 3.0 IGO. (in Russian).
9. Unger T., Borghi C., Charchar F., et al. 2020 International Society of Hypertension global hypertension practice guidelines. J Hypertens, 2020, vol. 38(6), pp. 982–1004. doi: 10.1097/HJH.0000000000002453.
10. Guideline for the pharmacological treatment of hypertension in adults [electronic resource]. Geneva: World Health Organization, 2021. Available at: https://www.who.int/publications/i/item/9789240033986 (accessed 24.10.2023).
11. About the Guidelines for the preclinical and clinical development of combination drugs : Recommendation of the Board of the Eurasian Economic Commission September 2, 2019 No. 25. Moscow. (in Russian).
12. White W. Cardiovascular risk and therapeutic intervention for the early morning surge in blood pressure and heart rate. Blood Press Monit, 2001, vol. 6, pp. 63-72. doi: 10.1097/00126097-200104000-00001.
13. Hansson L. Why don’t you do as I tell you? Compliance and antihypertensive regimens. Int J Clin Pract, 2002, vol. 56, pp. 191-196.
14. Irbesartan + hydrochlorothiazide. General characteristics of the drug. Agreed by the Ministry of Health of the Republic of Belarus. Order of the Ministry of Health of the Republic of Belarus dated July 26, 2023 No. 110 (in Russian).
15. Bova A. The place of angiotensin II receptor antagonists in clinical practice. Medical news, 2009, vol. 6, pp. 11-15. (in Russian).
16. Lindholm L.H., Ibsen H., Dahlöf B., et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint Reduction in Hypertension Study (LIFE): a randomised trial against atenolol. Lancet, 2002, vol. 359, pp. 1004-1010. doi: 10.1016/S0140-6736(02)08090-X.
17. Lindholm L.H., Persson M., Alaupovic P., et al. Metabolic outcome during 1 year in newly detected hypertensives: results of the antihypertensive treatment and lipid profile in a North of Sweden efficacy evaluation (ALPINE) study. J Hypertens, 2003, vol. 21, pp. 1563-1574. doi: 10.1097/01.hjh.0000084723.53355.76.
18. Chazova I.E., Ratova L.G. Combination therapy of arterial hypertension. M.: Media-Medika, 2007, pp. 86-94. (in Russian).
19. Malchikova S.V., Tarlovskaya E.I. Pleiotropic effects of various options for combination therapy for arterial hypertension. Cardiovascular Therapy and Prevention, 2009; 8(2). 33 – 38 p. (in Russian).
20. Bubnova M.G. Pleiotropic activity of antihypertensive drugs in atherothrombogenesis. Nebivolol: empowering and reducing limitations. Cardiovascular Therapy and Prevention, 2008, vol. 7(6), pp. 94-104. (in Russian).
21. Kochar M., Guthrie R., Triscari J., Kassler-Taub K., Reeves R. Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension. Am J Hypertens, 1999, vol. 12(8 Pt 1), pp. 797–805. doi: 10.1016/s0895-7061(99)00053-9.
22. Raskin P., Guthrie R., Flack J., Reeves R., Saini R. The long-term antihypertensive activity and tolerability of irbesartan with hydrochlorothiazide. J Hum Hypertens, 1999, vol. 13(10), pp. 683-687. doi: 10.1038/sj.jhh.1000888.
23. Howe P., Phillips P., Saini R., Kassler-Taub K. The antihypertensive efficacy of the combination of irbesartan and hydrochlorothiazide assessed by 24-hour ambulatory blood pressure monitoring. Irbesartan Multicenter Study Group. Clin Exp Hypertens, 1999, vol. 21(8), pp. 1373-96. doi: 10.3109/10641969909070855.
24. Coca A., Calvo C., Sobrino J., Gómez E., López-Paz J., Sierra C., Bragulat E., de la Sierra A. Once-daily fixed-combination irbesartan 300 mg/ hydrochlorothiazide 25 mg and circadian blood pressure profile in patients with essential hypertension. Clin Ther, 2003, vol. 25(11), pp. 2849-64. doi: 10.1016/s0149-2918(03)80338-7.
25. Neutel J., Saunders E., Bakris G., Cushman W., Ferdinand K., Ofili E., Sowers J., Weber M. INCLUSIVE Investigators. The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial. J Clin Hypertens (Greenwich), 2005, vol. 7(10), pp. 578-586. doi: 10.1111/j.1524-6175.2004.04720.x.
26. Sowers J., Neutel J., Saunders E., et al. Antihypertensive efficacy of Irbesartan/HCTZ in men and women with the metabolic syndrome and type 2 diabetes. J Clin Hypertens (Greenwich), 2006, vol. 8(7), pp. 470-480. doi: 10.1111/j.1524-6175.2006.05486.x.
27. Schrader J., Bramlage P., Luders S., Thoenes M., Schirmer A., Paar D. BP goal achievement in patients with uncontrolled hypertension: results of the treat-to-target post-marketing survey with irbesartan. Clin Drug Investig, 2007, vol. 27(11), pp. 783-796. doi: 10.2165/00044011-200727110-00005.
28. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet, 2003, vol. 362(9395), pp. 1527-1535. doi: 10.1016/s0140-6736(03)14739-3.
29. Neutel J., Franklin S., Oparil S., Bhaumik A., Ptaszynska A., Lapuerta P. Efficacy and safety of irbesartan/HCTZ combination therapy as initial treatment for rapid control of severe hypertension. J Clin Hypertens (Greenwich), 2006, vol. 8(12), pp. 850-857. doi: 10.1111/j.1524-6175.2006.05676.x.
30. Neutel J., Franklin S., Lapuerta P., Bhaumik A., Ptaszynska A. A comparison of the efficacy and safety of irbesartan/HCTZ combination therapy with irbesartan and HCTZ monotherapy in the treatment of moderate hypertension. J Hum Hypertens, 2008, vol. 22, pp. 266-274. doi: 10.1038/sj.jhh.1002293.
31. Dezii C. A retrospective study of persistence with single-pill combination therapy vs. concurrent two-pill therapy in patients with hypertension. Manag Care, 2000, vol. 9(9 Suppl), pp. 2-6.
32. Gerbino P., Shoheiber O. Adherence patterns among patients treated with fixed-dose combination versus separate antihypertensive agents. Am J Health Syst Pharm, 2007, vol. 64(12), pp. 1279-1283. doi: 10.2146/ajhp060434.
33. Fouassier D., Blanchard A., Fayol A., Bobrie G., Boutouyrie P., Azizi M., Hulot J.S. Sequential nephron blockade with combined diuretics improves diastolic function in patients with resistant hypertension. ESC Heart Fail, 2020, vol. 7(5), pp. 2561-2571. doi: 10.1002/ehf2.12832.
34. Napoli C., Omboni S., Borghi C. ; ZAMES (Zofenopril in Advanced MEtabolic Syndrome) Study Group. Fixed-dose combination of zofenopril plus hydrochlorothiazide vs. irbesartan plus hydrochlorothiazide in hypertensive patients with established metabolic syndrome uncontrolled by previous monotherapy. The ZAMES study (Zofenopril in Advanced MEtabolic Syndrome). J Hypertens, 2016, vol. 34(11), pp. 2287-2297. doi: 10.1097/HJH.0000000000001079.
35. Vitale C., Marazzi G., Iellamo F., Spoletini I., Dall’Armi V., Fini M., Volterrani M. Effects of nebivolol or irbesartan in combination with hydrochlorothiazide on vascular functions in newly-diagnosed hypertensive patients: the NINFE (Nebivololo, Irbesartan Nella Funzione Endoteliale) study. Int J Cardiol, 2012, vol. 155(2), pp. 279-284. doi: 10.1016/j.ijcard.2011.10.099.
36. Asmar R., Oparil S. Comparison of the antihypertensive efficacy of irbesartan/HCTZ and valsartan/HCTZ combination therapy: impact of age and gender. Clin E xp Hyper tens, 2010, vol. 32(8), pp. 499-503. doi: 10.3109/10641963.2010.496509.
37. Neutel J.M., Smith D. Ambulatory blood pressure comparison of the anti-hypertensive efficacy of fixed combinations of irbesartan/hydrochlorothiazide and losartan/hydrochlorothiazide in patients with mild-to-moderate hypertension. J Int Med Res, 2005, vol. 33(6), pp. 620-631. doi: 10.1177/147323000503300603.
38. Koroleva A.A., Zhuravkov Yu.L. Nephroprotection in a patient with diabetes mellitus and arterial hypertension: focus on irbesartan. Medical News, 2020, no. 7(310), pp. 47-52. (in Russian).
Review
For citations:
Kozhanova I.N. Fixed-dose irbesartan/hydrochlorothiazide combination in the treatment of arterial hypertension. Emergency Cardiology and Cardiovascular Risks journal. 2023;7(2):2021-2031. (In Russ.) https://doi.org/10.51922/2616-633X.2023.7.2.2021
Views:
7
Email this article 